Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘Baylor’

How Will Adoptive Cell Therapy Crack Solid Tumours? – This was the provocative question raised by the title of Dr Malcolm Brenner’s keynote lecture at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium held last week in San Francisco, ”Adoptive T cell Therapy: Target Solid Tumors by CARs or TCRs?”

Malcolm K Brenner, MD PhD is the Director of the Center for Cell and Gene Therapy at Baylor College of Medicine in Houston, Texas.

ASCO have just named CAR-T cell immunotherapy as its “2018 Cancer Advance of the Year” so it’s timely to take a look at where we are in the adoptive cell therapy field and where it may be going?

We’ve been writing about adoptive cell therapies (ACT) such as CAR T cell therapy since 2011.  Indeed, I vividly recall one of my early interviews about it at ASH 2013 (See post: Juno Therapeutics takes on Novartis and seeks to revolutionize the treatment of blood cancers – an interview with Renier Brentjens)”.

In recent years, CAR T cell therapy has made tremendous progress in hematologic malignancies, gaining FDA approval last year in relapsed/refratory paediatric ALL and non-Hodgkin lymphoma (NHL). We have not seen the same efficacy in solid tumours as yet, and this remains one of the key challenges in the field today.

In this post, we take a look at the perspectives Dr Brenner offered in his keynote lecture at ASCO-SITC and the potential impact they may have on the landscape.

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Aloha! It will soon be time to pack your Hawaiian shirts for the forthcoming BMT Tandem Meeting in Hawaii (Twitter #BMTTandem16 – what a long hashtag!!)


Commonly known as “Tandem,” it’s the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT).

Hawaii is great location for a meeting in February, and one that I’m sure will generate a lot of envy for those who can’t attend and are stuck in the winter cold and chill. Who said we don’t go the “extra mile” for BSB subs?

One of the presentations I’m looking forward to hearing at Tandem is by Ann Leen, PhD, who is an Associate Professor at Baylor College of Medicine.

Dr Leen will be talking about “Immunotherapy for Lymphoma using T cells Targeting Multiple Tumor-Associated Antigens.

At last December’s ASH annual meeting, Dr Leen presented preliminary data with this novel approach in patients with Hodgkin’s Lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). After her ASH presentation, she kindly spoke to BSB.

This post is part of our post-meeting ASH15 coverage, and our ongoing coverage of some of the exciting developments in immuno-oncology.  In case you missed it, do check out the ASH interview with Seattle Genetics CEO Clay Siegall, PhD.

Subscribers can login to read more or you can purchase access.

This content is restricted to subscribers

It’s that time of the month where the BSB readers get their chance to put us on the hot spot!

SITC 2015 Land GrabHere, we take a look at reader questions that have been submitted and argue the toss – is there evidence preclinically or clinically that is useful or instructive?

We can’t promise to answer every question, sometimes there simply isn’t any data to help either way.

This week, the topic is CAR T cell therapies, a subject that seems to be very high on many people’s minds and many of you had similar questions, so here goes…  

Subscribers can log in to learn more insights…

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!